Literature DB >> 6751510

Treatment of blepharitis and blepharoconjunctivitis: comparison of gentamicin-betamethasone, gentamicin alone and placebo.

W B Jackson, W M Easterbrook, W E Connolly, W D Leers.   

Abstract

At two university centres 46 patients presenting with symptomatic infective blepharitis or blepharoconjunctivitis participated in a double-blind study of a new antibiotic-steroid ointment containing gentamicin and betamethasone. There was no significant difference in response to 2 weeks of therapy between the patients treated with this ointment and those treated with either an ointment containing gentamicin alone or a placebo ointment. There was also no significant correlation between the clinical response and the results of the bacterial cultures of swabs obtained at the beginning and the end of the study. However, the patients treated with the placebo had a much higher rate of recurrence of their symptoms over a 6-week follow-up period. The patients who before treatment had associated rosacea, dry eyes and a long duration of symptoms showed a poor response to therapy.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6751510

Source DB:  PubMed          Journal:  Can J Ophthalmol        ISSN: 0008-4182            Impact factor:   1.882


  3 in total

Review 1.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

Review 2.  Therapeutic Strategies to Treat Dry Eye in an Aging Population.

Authors:  Nisreen S Ezuddin; Karam A Alawa; Anat Galor
Journal:  Drugs Aging       Date:  2015-07       Impact factor: 3.923

3.  A prospective study determining the efficacy of topical 0.5% levofloxacin on bacterial flora of patients with chronic blepharoconjunctivitis.

Authors:  Yazmin Yactayo-Miranda; Christopher N Ta; Lisa He; Thomas C Kreutzer; Martin M Nentwich; Anselm Kampik; Herminia Mino de Kaspar
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-02-11       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.